SEC Form 4 · accession 0001079973-26-001175
Starling Oncology, Inc. · STLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brad Hively
Director
Period of report
Aug 21, 2026
Accepted (ET)
Aug 24, 2026 · 5:11 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001799191
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 21, 2026 | S | 298,853 | $6.5126 | D | 411,976 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.37 to $6.75 per share. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided.